ストックスクリーナーアプリを入手
32.12
0.74%
-0.12
前日終値:
$32.24
開ける：
$32.55
24時間の取引高:
243.79K
Relative Volume:
0.39
時価総額：
$2.18B
収益：
-
当期純損益:
$-64.16M
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
$-69.06M
1週間 パフォーマンス:
-9.85%
1か月 パフォーマンス:
-12.83%
6か月 パフォーマンス:
+10.46%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$31.28
$32.55
1週間の範囲:
$31.28
$35.83
52週間の値動き範囲:
$25.77
$50.23
Cg Oncology Inc Stock (CGON) Company Profile
CGON を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| CGON | 31.96 | 2.18B | 0 | -64.16M | -69.06M | 0.00 |
| VRTX | 449.18 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.98 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.38 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.49 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.97 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-14 | 開始されました | H.C. Wainwright | Buy |
Cg Oncology Inc (CGON) 最新ニュース
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting - The Manila Times
CG Oncology to Present Phase 3 Trial Results for Bladder Cancer Treatment at SUO Meeting | CGON Stock News - StockTitan
CG Oncology, Inc. to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology 25th Annual Meeting - Marketscreener.com
CG Oncology, Inc. (NASDAQ:CGON) Sees Large Decline in Short Interest - MarketBeat
CG Oncology FY2024 EPS Estimate Lifted by Cantor Fitzgerald - MarketBeat
Los Angeles Capital Management LLC Takes $832,000 Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Lifesci Capital Boosts Earnings Estimates for CG Oncology - Defense World
FY2024 EPS Estimates for CG Oncology Raised by HC Wainwright - MarketBeat
CG Oncology FY2024 EPS Forecast Increased by Lifesci Capital - MarketBeat
CG Oncology, Inc. (CGON) Quarterly 10-Q Report - Quartzy
CG Oncology Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
CG Oncology (NASDAQ:CGON) Releases Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
HC Wainwright Reiterates "Buy" Rating for CG Oncology (NASDAQ:CGON) - MarketBeat
CG Oncology Posts $20.4M Loss, Maintains $540M Cash Reserve Through 2027 | CGON Stock News - StockTitan
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer - The Manila Times
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating - The Bakersfield Californian
CG Oncology, Inc. Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer - Marketscreener.com
TimesSquare Capital Management LLC Purchases 94,010 Shares of CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
CG Oncology's Breakthrough Bladder Cancer Drug Scores Second Nature Medicine Publication | CGON Stock News - StockTitan
CG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Receives $63.88 Consensus Target Price from Analysts - MarketBeat
CG Oncology, first biotech IPO for 2024, surges on trading debut - MSN
Vanguard Group Inc's Strategic Acquisition of CG Oncology Inc Sh - GuruFocus.com
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
CG Oncology To Report Final Results From CORE-001 Bladder Cancer Study Next Month - RTTNews
CG Oncology, Inc. (NASDAQ:CGON) Short Interest Down 14.5% in October - Defense World
UBS Initiates Coverage of CG Oncology (CGON) with Buy Recommendation - MSN
CG Oncology (NASDAQ:CGON) Coverage Initiated by Analysts at UBS Group - MarketBeat
Oncolytic Adenovirus Market Targets USD 250 Billion Valuation by 2033 at a 7.5% of CAGR - PharmiWeb.com
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Oncolytic Virus Market Size is Set for Rapid Growth as Innovative - openPR
17,595 Shares in CG Oncology, Inc. (NASDAQ:CGON) Acquired by SG Americas Securities LLC - MarketBeat
Down rounds don’t aid post-IPO performance - BioCentury
CG Oncology (NASDAQ:CGON) Earns "Buy" Rating from Bank of America - MarketBeat
The Potential Rise in the Price of Cg Oncology Inc. (CGON) following insiders activity - Knox Daily
Get in on Cg Oncology Inc.’s (CGON) buy-in window today! - SETE News
Renaissance Technologies LLC Grows Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Marshall Wace LLP Acquires New Shares in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth - Simply Wall St
Multiple players rev their Engenes in bladder cancer - BioWorld Online
Point72 Asset Management L.P. Sells 75,827 Shares of CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Want To Improve Study Startup? Get More Efficient - Clinical Leader
We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth - Yahoo Finance
How does Cg Oncology Inc. (CGON) change from a tortoise to a hare? - SETE News
RBC Capital Mkts initates Cg Oncology Inc. (CGON) stock to an Outperform - Knox Daily
CG Oncology, Inc. (NASDAQ:CGON) Shares Sold by Perceptive Advisors LLC - MarketBeat
Ensign Peak Advisors Inc Buys New Holdings in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Wall Street SWOT: CG Oncology stock poised for growth in bladder cancer market - Investing.com
Midday Stock Roundup: Indie Shares Down 5% - Orange County Business Journal
Wall Street SWOT: CG Oncology stock poised for growth in bladder cancer market By Investing.com - Investing.com South Africa
Goldman Sachs maintains $52 target on CG Oncology shares By Investing.com - Investing.com Canada
Cg Oncology Inc (CGON) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):